LONDON, March 23, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), XOMA Corporation (NASDAQ: XOMA), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and BioLine RX Ltd (NASDAQ: BLRX). Free research report on Geron can be accessed at http://get.Investor-Edge.com/pdf/?c=Geron&d=23-Mar-2015&s=GERN. The US markets on Friday, March 20, 2015, ended on a positive note as the Dow Jones Industrial Average finished at 18,127.65, up 0.94% and the NASDAQ Composite closed at 5,026.42, up 0.68%. The S&P 500 finished the session 0.90% higher at 2,108.10. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 866.47, up 0.78%, with the index advancing 9.72% in the previous three months. Register for your complimentary reports at the links given below.
Geron Corp.'s stock declined 3.63%, to close the day at $3.98. The stock recorded a trading volume of 5.85 million shares, above its three months average volume of 3.94 million shares. The company's shares oscillated between $3.95 and $4.25 during the session. Over the last one month and over the previous three months, Geron Corp.'s shares have surged 25.95% and 22.09%, respectively. Further, the stock has rallied 90.60% in the past one year. The company is trading above its 50-day and 200-day moving averages. Geron Corp.'s 50-day moving average of $3.35 is above its 200-day moving average of $2.82. Additionally, the stock has a Relative Strength Index (RSI) of 58.51. Sign up and read the free notes on GERN at:
On Friday, shares in Lexicon Pharmaceuticals Inc. recorded a trading volume of 4.62 million shares, higher than its three months average volume of 1.89 million shares. The stock ended the day at $1.10, which was 3.51% below its previous day's closing of $1.14, and registered an intraday range of $1.09 and $1.13. Lexicon Pharmaceuticals Inc.'s shares have surged 18.28% in the last one month and 28.22% in the past three months, while the stock has fallen by 1.79% in the previous three trading sessions. The company is trading above its 50-day moving average of $0.98, which is below the 200-day moving average of $1.27. Furthermore, shares of Lexicon Pharmaceuticals Inc. have an RSI of 57.94. The complimentary notes on LXRX can be downloaded as in PDF format at:
XOMA Corp.'s stock declined 3.62% to end Friday's session at $3.99. The stock recorded a trading volume of 6.29 million shares, above its three months average volume of 2.51 million shares. The company's shares fluctuated between $3.95 and $4.28 during the session. XOMA Corp.'s shares have gained 1.79% in the previous three trading sessions. However, the stock has fallen by 1.48% over the last one month and 0.50% over the past three months. The company is trading above its 50-day moving average. XOMA Corp.'s 200-day moving average of $4.15 is above its 50-day moving average of $3.66. Additionally, the stock has an RSI of 57.70. Register for free on Investor-Edge and access the latest research on XOMA at:
On Friday, shares in Spectrum Pharmaceuticals Inc. fluctuated between $6.15 and $6.55 before ending the session 3.74% lower at $6.17. The stock reported a trading volume of 2.41 million shares, higher than its three months average volume of 1.22 million shares. Spectrum Pharmaceuticals Inc.'s stock has lost 3.22% in the previous three trading sessions, 17.29% in the last one month, and 13.95% in the past three months. The company is trading below its 50-day and 200-day moving averages of $6.70 and $7.42, respectively. Moreover, shares of Spectrum Pharmaceuticals Inc. have an RSI of 41.52. The complete research on SPPI is available for free at:
BioLine RX Ltd's stock finished Friday's session 1.48% higher at $2.06. A total of 0.87 million shares were traded, which was above its three months average volume of 0.62 million shares. The stock vacillated between $2.00 and $2.12 during the session. Over the previous three trading sessions and over the past three months, BioLine RX Ltd's shares have gained 1.98% and 19.77%, respectively. However, over the last one month, the stock has lost 14.88%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $2.05 is greater than its 200-day moving average of $1.78. BioLine RX Ltd's stock has an RSI of 47.88. Free in depth research on BLRX is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.